Log in

NASDAQ:JYNT - Joint Stock Price, Forecast & News

-0.31 (-2.02 %)
(As of 02/28/2020 01:57 AM ET)
Today's Range
Now: $15.03
50-Day Range
MA: $16.27
52-Week Range
Now: $15.03
Volume110,600 shs
Average Volume91,995 shs
Market Capitalization$208.36 million
P/E Ratio75.15
Dividend YieldN/A
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States. Read More…

Industry, Sector and Symbol

Industry Patent owners & lessors
Current SymbolNASDAQ:JYNT



Sales & Book Value

Annual Sales$31.79 million
Cash Flow$0.15 per share
Book Value$0.17 per share


Net Income$250,000.00


Market Cap$208.36 million
Next Earnings Date3/5/2020 (Confirmed)
OptionableNot Optionable

Receive JYNT News and Ratings via Email

Sign-up to receive the latest news and ratings for JYNT and its competitors with MarketBeat's FREE daily newsletter.

Joint (NASDAQ:JYNT) Frequently Asked Questions

What is Joint's stock symbol?

Joint trades on the NASDAQ under the ticker symbol "JYNT."

How were Joint's earnings last quarter?

Joint Corp (NASDAQ:JYNT) announced its quarterly earnings results on Thursday, November, 7th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.01. The company earned $12.73 million during the quarter, compared to the consensus estimate of $11.60 million. Joint had a net margin of 6.57% and a return on equity of 104.54%. View Joint's Earnings History.

When is Joint's next earnings date?

Joint is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Joint.

How can I listen to Joint's earnings call?

Joint will be holding an earnings conference call on Thursday, March 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for JYNT?

5 Wall Street analysts have issued twelve-month price objectives for Joint's shares. Their forecasts range from $23.00 to $32.00. On average, they expect Joint's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 79.6% from the stock's current price. View Analyst Price Targets for Joint.

What is the consensus analysts' recommendation for Joint?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Joint in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Joint.

What are Wall Street analysts saying about Joint stock?

Here are some recent quotes from research analysts about Joint stock:
  • 1. According to Zacks Investment Research, "The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company's plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. " (1/14/2020)
  • 2. Maxim Group analysts commented, "Market close, JYNT reported relatively inline 2Q19 revenue results and reiterated 2019 guidance. The company opened 14 franchise clinics in 2Q19 versus our estimate of 17, for a total of 417 franchises. JYNT also opened one greenfield clinic bringing that total up to 51. We are increasing our 2020 revenue estimate as we expect the company to continue to open franchise and greenfield clinics while expanding its national footprint. Also, we are introducing our 2020 quarterly estimates." (8/9/2019)

Has Joint been receiving favorable news coverage?

Headlines about JYNT stock have trended very negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Joint earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View News Stories for Joint.

Who are some of Joint's key competitors?

What other stocks do shareholders of Joint own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Joint investors own include Advanced Micro Devices (AMD), Starbucks (SBUX), Adobe (ADBE), Catalyst Pharmaceuticals (CPRX), Etsy (ETSY), Lululemon Athletica (LULU), Universal Display (OLED), Aurora Cannabis (ACB), salesforce.com (CRM) and Walt Disney (DIS).

Who are Joint's key executives?

Joint's management team includes the folowing people:
  • Mr. Peter D. Holt, CEO, Pres & Director (Age 60)
  • Jake Singleton, Chief Financial Officer (Age 37)
  • Mr. Jorge Armenteros, VP of Operations
  • Dr. James Edwards, Chief Chiropractic & Compliance Officer
  • Mr. Craig P. Colmar, Sec. (Age 66)

When did Joint IPO?

(JYNT) raised $20 million in an initial public offering on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.

Who are Joint's major shareholders?

Joint's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (4.66%), State Street Corp (1.82%), Acadian Asset Management LLC (1.74%), THB Asset Management (1.28%), Goldman Sachs Group Inc. (1.19%) and Geode Capital Management LLC (1.18%). Company insiders that own Joint stock include Glenn J Krevlin, James H Amos Jr, John P Meloun, Peter D Holt and Ronald V Davella. View Institutional Ownership Trends for Joint.

Which major investors are selling Joint stock?

JYNT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Granite Investment Partners LLC, Renaissance Technologies LLC, Cadence Capital Management LLC, Russell Investments Group Ltd., Oxford Asset Management LLP, Spark Investment Management LLC and Acadian Asset Management LLC. Company insiders that have sold Joint company stock in the last year include Glenn J Krevlin and Ronald V Davella. View Insider Buying and Selling for Joint.

Which major investors are buying Joint stock?

JYNT stock was purchased by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Verus Capital Partners LLC, Bank of Montreal Can, Marshall Wace LLP, Globeflex Capital L P, California Public Employees Retirement System, Mesirow Financial Investment Management Inc. and Marshall Wace North America L.P.. Company insiders that have bought Joint stock in the last two years include James H Amos Jr and Peter D Holt. View Insider Buying and Selling for Joint.

How do I buy shares of Joint?

Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Joint's stock price today?

One share of JYNT stock can currently be purchased for approximately $15.03.

How big of a company is Joint?

Joint has a market capitalization of $208.36 million and generates $31.79 million in revenue each year. The company earns $250,000.00 in net income (profit) each year or $0.04 on an earnings per share basis. Joint employs 138 workers across the globe.View Additional Information About Joint.

What is Joint's official website?

The official website for Joint is http://www.thejoint.com/.

How can I contact Joint?

Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]

MarketBeat Community Rating for Joint (NASDAQ JYNT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  227 (Thanks for Voting!)
Underperform Votes:  228 (Thanks for Voting!)
Total Votes:  455
MarketBeat's community ratings are surveys of what our community members think about Joint and other stocks. Vote "Outperform" if you believe JYNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JYNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: What is a Swap?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel